Last reviewed · How we verify
Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib
Approved treatments
- PF-06863135 + lenalidomide · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib patent landscape — cliff calendar, originator estates, attackable patents
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib treatment landscape brief
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib treatment updates RSS
Frequently asked questions about Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib
What drugs treat Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib?
Tracked treatments include PF-06863135 + lenalidomide.
What is the treatment for Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib?
Standard treatment for Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib includes PF-06863135 + lenalidomide. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib patent cliff · Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib CI report
- Treatment: PF-06863135 + lenalidomide · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing